ALLOAllogene TherapeuticsSigning up patients
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 250 (planned)
- Started
- Jun 18, 2024
- Main results expected
- Dec 2027
- Fully finished
- Dec 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-free survival per independent review committee assessment
Measured over: Up to 60 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06500273 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC